- Study from NCPA sheds new light on med synchronization programs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- NACDS, NCPA, GPhA express support for Drug Quality and Security Act
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PRINCETON, N.J. — Sandoz has launched an authorized generic drug for treating a disease commonly known as pre-leukemia, the company said on Monday.
Sandoz, the generics division of Novartis, announced the launch of azacitidine injection, an authorized generic version of Celgene's Vidaza, in 100-mg, single-use vials. The drug is used to treat myelodysplastic syndrome, a bone marrow disease. Authorized generics are branded drugs marketed at a discounted price under their generic names, usually through a third-party company under contract with the branded drug's manufacturer.
Vidaza had sales of $373 million during the 12-month period that ended in May, according to IMS Health.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.